Opko Health(OPK)
MIAMI, FL
DiagnosticsFocus: Biologics, Vaccines, Diagnostics, etc.
Opko Health is a life sciences company focused on Biologics, Vaccines, Diagnostics, etc..
Infectious DiseasesVaccines
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
Aquashunt
GlaucomaClinical Trials (1)
NCT00834223A Prospective, Multicenter, Open-label, Safety and Preliminary Efficacy Study of the Surgical Implantation of OPKO's Glaucoma Drainage Device (AquashuntTM) in Patients With Refractory Chronic Forms of Open Angle Glaucoma (OAG)
N/AVis Glyc Neo
Dry Eye SyndromesClinical Trials (1)
NCT04063644Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients
N/AENKO 1
Osteoarthritis, KneeClinical Trials (1)
NCT03762408Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis.
N/APROGEN
ACL ReconstructionClinical Trials (1)
NCT03355651Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction
N/AMeasurement of four prostate-specific kallikreins for the 4Kscore Test when serum stored uncentrifuged
Prostate CancerClinical Trials (1)
NCT041307764Kscore Using Serum Stored Uncentrifuged
N/AMOD-5014
Hemophilia AClinical Trials (1)
NCT02418793A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Phase 1E1 and G1
Type 2 DiabetesClinical Trials (1)
NCT00239187A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1
Phase 1MOD-4023
Growth Hormone DeficiencyClinical Trials (1)
NCT02418767Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers
Phase 1CTAP201 Injection
Chronic Kidney DiseaseClinical Trials (1)
NCT00792857Comparison of I.V. CTAP201 and Doxercalciferol (Hectorol) in Subjects With Chronic Kidney Disease (CKD) and Secondary Hyperparathyroidism (SHPT)
Phase 1bevasiranib
Macular DegenerationClinical Trials (1)
NCT00722384Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
Phase 1E1 and G1
Type 1 DiabetesClinical Trials (1)
NCT00239148A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1
Phase 1LY2428757
Diabetes Mellitus, Type 2CTAP101 Capsules
Breast CancerClinical Trials (1)
NCT02274623Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
Phase 1LY2944876
Healthy VolunteersClinical Trials (1)
NCT02188303A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants
Phase 1CTAP101 Capsules
Vitamin D InsufficiencyClinical Trials (1)
NCT03660800Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects
Phase 1MOD-4023
HealthyClinical Trials (1)
NCT01060722MOD-4023 Study in Healthy Male Volunteers
Phase 1MDX2301
COVID -19Clinical Trials (1)
NCT07445971A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
Phase 1SAR441236
HIV-1-infectionCTAP101 Capsules
Chronic Kidney DiseaseClinical Trials (1)
NCT00888069Pharmacokinetics and Safety Pilot Study of Single-Dose Oral and Intravenous CTAP101 in Stage 3 and 4 Chronic Kidney Disease Subjects
Phase 1Somatrogon
Healthy Male VolunteersClinical Trials (1)
NCT03810664A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations
Phase 1MOD-6031
ObesityClinical Trials (1)
NCT02692781A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects
Phase 1Phase 1
Clinical Trials (1)
NCT01357421Effects of TT301 on Cytokine Levels Post Endotoxin Challenge
Phase 1EMZ702
Chronic Hepatitis CClinical Trials (1)
NCT00230854Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin
Phase 1Phase 1
Clinical Trials (1)
NCT02919800A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male
Phase 1MDX2003
LymphomaClinical Trials (1)
NCT07249905Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Phase 1/2MDX2001
Biliary Tract CancerClinical Trials (1)
NCT06239194Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Phase 1/2MDX2004
Advanced TumorsClinical Trials (1)
NCT07110584Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
Phase 1/2ELND005
Alzheimer's DiseaseClinical Trials (1)
NCT01735630Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Phase 2Lunacalcipol 180
Stage 5 Chronic Kidney Disease (CKD)Clinical Trials (1)
NCT01453634Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)
Phase 2CTA018 Injection
Chronic Kidney DiseaseClinical Trials (1)
NCT00742716Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
Phase 2MOD-4023
Adult Growth Hormone DeficiencyClinical Trials (1)
NCT01225666MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)
Phase 2MOD-4023
Growth Hormone Deficiency (GHD)Clinical Trials (1)
NCT02500316Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Phase 2ELND005
Bipolar 1 DisorderClinical Trials (1)
NCT01674010Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
Phase 2Phase 2
Clinical Trials (1)
NCT01592500Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Phase 2TT223 with Metformin and/or TZD
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT00743002A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione
Phase 2ELND005
Down SyndromeClinical Trials (1)
NCT01791725A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
Phase 2OPK-88003
Type 2 Diabetes MellitusClinical Trials (1)
NCT03406377Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
Phase 2Group 1 ELND005
Alzheimer's DiseaseClinical Trials (1)
NCT01766336A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease
Phase 2Bevasiranib
Macular DegenerationClinical Trials (1)
NCT00259753Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration
Phase 2LY2944876
Diabetes Mellitus, Type 2Clinical Trials (1)
NCT02119819A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes
Phase 2Group-1
Benign Prostatic HyperplasiaClinical Trials (1)
NCT03297398Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
Phase 2Placebo Control
Alzheimer DiseaseClinical Trials (1)
NCT00568776ELND005 in Patients With Mild to Moderate Alzheimer's Disease
Phase 2bevasiranib
Diabetic Macular EdemaClinical Trials (1)
NCT00306904Safety and Efficacy Study of Small Interfering RNA Molecule (Cand5) to Treat Diabetic Macular Edema
Phase 2CTA018 cream
PsoriasisClinical Trials (1)
NCT00384098Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
Phase 2ELND005
Alzheimer's DiseaseClinical Trials (1)
NCT00934050ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Phase 2Calcifediol Oral Capsule
Secondary Hyperparathyroidism Due to Renal CausesClinical Trials (1)
NCT03602261Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
Phase 2Rayaldee
COVID-19Clinical Trials (1)
NCT04551911Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
Phase 2Cohort 1 CTAP101 Capsules- 60µg
Chronic Kidney DiseaseClinical Trials (1)
NCT01219855Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)
Phase 2/3Phase 3
Clinical Trials (1)
NCT02968004Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
Phase 3Phase 3
Clinical Trials (1)
NCT05543928Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 48 clinical trials
SEC Filings: 2 available
Financials (FY2025)
Revenue
$863M14%
R&D Spend
$90M(10%)21%
Net Income
-$189MCash
$427M